For the first time, U.S. infants saw dramatically fewer RSV hospitalizations thanks to new maternal vaccines and nirsevimab, highlighting the urgent need for early, widespread prevention each season.
Study: Interim Evaluation of Respiratory Syncytial Virus Hospitalization Rates Among Infants and Young Children After Introduction of Respiratory Syncytial Virus Prevention Products — United States, October 2024–February 2025. Image Credit: Jarun Ontakrai / Shutterstock
In a recent report published in the Morbidity and Mortality Weekly Report, a group of researchers evaluated changes in respiratory syncytial virus (RSV)-associated hospitalization rates among children under five following the widespread availability of maternal vaccination and nirsevimab during the 2024-2025 season.
Because this was…